Cargando…

An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment

SIMPLE SUMMARY: One of the important efforts in the treatment of cancers is to achieve targeted drug delivery by nanocarriers to be more effective and reduce adverse effects. However, due to the adverse responses of nanocarriers in clinical trials due to the very weak EPR effects, doubts have been r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharifi, Majid, Cho, William C., Ansariesfahani, Asal, Tarharoudi, Rahil, Malekisarvar, Hedyeh, Sari, Soyar, Bloukh, Samir Haj, Edis, Zehra, Amin, Mohamadreza, Gleghorn, Jason P., Hagen, Timo L. M. ten, Falahati, Mojtaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220781/
https://www.ncbi.nlm.nih.gov/pubmed/35740534
http://dx.doi.org/10.3390/cancers14122868
_version_ 1784732453404934144
author Sharifi, Majid
Cho, William C.
Ansariesfahani, Asal
Tarharoudi, Rahil
Malekisarvar, Hedyeh
Sari, Soyar
Bloukh, Samir Haj
Edis, Zehra
Amin, Mohamadreza
Gleghorn, Jason P.
Hagen, Timo L. M. ten
Falahati, Mojtaba
author_facet Sharifi, Majid
Cho, William C.
Ansariesfahani, Asal
Tarharoudi, Rahil
Malekisarvar, Hedyeh
Sari, Soyar
Bloukh, Samir Haj
Edis, Zehra
Amin, Mohamadreza
Gleghorn, Jason P.
Hagen, Timo L. M. ten
Falahati, Mojtaba
author_sort Sharifi, Majid
collection PubMed
description SIMPLE SUMMARY: One of the important efforts in the treatment of cancers is to achieve targeted drug delivery by nanocarriers to be more effective and reduce adverse effects. However, due to the adverse responses of nanocarriers in clinical trials due to the very weak EPR effects, doubts have been raised in this regard. In this study, an attempt has been made to take a critical look at EPR approaches to enable the convergence of previous papers and the EPR critics to reach an appropriate therapeutic path. Although the effectiveness of EPR is highly variable due to the complex microenvironment of the tumor, there is high hope for cancer treatment by describing new strategies to overcome the challenges of EPR effect. Furthermore, in this paper an attempt was made to provide a reliable path for future to develop cancer therapeutics based on EPR effect. ABSTRACT: The enhanced permeability and retention (EPR) effect in cancer treatment is one of the key mechanisms that enables drug accumulation at the tumor site. However, despite a plethora of virus/inorganic/organic-based nanocarriers designed to rely on the EPR effect to effectively target tumors, most have failed in the clinic. It seems that the non-compliance of research activities with clinical trials, goals unrelated to the EPR effect, and lack of awareness of the impact of solid tumor structure and interactions on the performance of drug nanocarriers have intensified this dissatisfaction. As such, the asymmetric growth and structural complexity of solid tumors, physicochemical properties of drug nanocarriers, EPR analytical combination tools, and EPR description goals should be considered to improve EPR-based cancer therapeutics. This review provides valuable insights into the limitations of the EPR effect in therapeutic efficacy and reports crucial perspectives on how the EPR effect can be modulated to improve the therapeutic effects of nanomedicine.
format Online
Article
Text
id pubmed-9220781
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92207812022-06-24 An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment Sharifi, Majid Cho, William C. Ansariesfahani, Asal Tarharoudi, Rahil Malekisarvar, Hedyeh Sari, Soyar Bloukh, Samir Haj Edis, Zehra Amin, Mohamadreza Gleghorn, Jason P. Hagen, Timo L. M. ten Falahati, Mojtaba Cancers (Basel) Review SIMPLE SUMMARY: One of the important efforts in the treatment of cancers is to achieve targeted drug delivery by nanocarriers to be more effective and reduce adverse effects. However, due to the adverse responses of nanocarriers in clinical trials due to the very weak EPR effects, doubts have been raised in this regard. In this study, an attempt has been made to take a critical look at EPR approaches to enable the convergence of previous papers and the EPR critics to reach an appropriate therapeutic path. Although the effectiveness of EPR is highly variable due to the complex microenvironment of the tumor, there is high hope for cancer treatment by describing new strategies to overcome the challenges of EPR effect. Furthermore, in this paper an attempt was made to provide a reliable path for future to develop cancer therapeutics based on EPR effect. ABSTRACT: The enhanced permeability and retention (EPR) effect in cancer treatment is one of the key mechanisms that enables drug accumulation at the tumor site. However, despite a plethora of virus/inorganic/organic-based nanocarriers designed to rely on the EPR effect to effectively target tumors, most have failed in the clinic. It seems that the non-compliance of research activities with clinical trials, goals unrelated to the EPR effect, and lack of awareness of the impact of solid tumor structure and interactions on the performance of drug nanocarriers have intensified this dissatisfaction. As such, the asymmetric growth and structural complexity of solid tumors, physicochemical properties of drug nanocarriers, EPR analytical combination tools, and EPR description goals should be considered to improve EPR-based cancer therapeutics. This review provides valuable insights into the limitations of the EPR effect in therapeutic efficacy and reports crucial perspectives on how the EPR effect can be modulated to improve the therapeutic effects of nanomedicine. MDPI 2022-06-10 /pmc/articles/PMC9220781/ /pubmed/35740534 http://dx.doi.org/10.3390/cancers14122868 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sharifi, Majid
Cho, William C.
Ansariesfahani, Asal
Tarharoudi, Rahil
Malekisarvar, Hedyeh
Sari, Soyar
Bloukh, Samir Haj
Edis, Zehra
Amin, Mohamadreza
Gleghorn, Jason P.
Hagen, Timo L. M. ten
Falahati, Mojtaba
An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment
title An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment
title_full An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment
title_fullStr An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment
title_full_unstemmed An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment
title_short An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment
title_sort updated review on epr-based solid tumor targeting nanocarriers for cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220781/
https://www.ncbi.nlm.nih.gov/pubmed/35740534
http://dx.doi.org/10.3390/cancers14122868
work_keys_str_mv AT sharifimajid anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT chowilliamc anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT ansariesfahaniasal anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT tarharoudirahil anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT malekisarvarhedyeh anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT sarisoyar anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT bloukhsamirhaj anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT ediszehra anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT aminmohamadreza anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT gleghornjasonp anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT hagentimolmten anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT falahatimojtaba anupdatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT sharifimajid updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT chowilliamc updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT ansariesfahaniasal updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT tarharoudirahil updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT malekisarvarhedyeh updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT sarisoyar updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT bloukhsamirhaj updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT ediszehra updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT aminmohamadreza updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT gleghornjasonp updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT hagentimolmten updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment
AT falahatimojtaba updatedreviewoneprbasedsolidtumortargetingnanocarriersforcancertreatment